Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects

doi:10.3748/wjg.v20.i24.7830

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 24

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15594)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

1015

WORD

333

HTML

11632

Figures (1-1)

228

Tables (1-6)

394

Sum=13602

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1118

Download

874

Sum=1992

Jun 28, 2014 (publication date) through May 8, 2024

Times Cited of This Article

Times Cited (72)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 28, 2014; 20(24): 7830-7848
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7830

Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects

Daniel Neureiter, Tarkan Jäger, Matthias Ocker, Tobias Kiesslich

Daniel Neureiter, Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria

Tarkan Jäger, Department of Surgery, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria

Matthias Ocker, Experimental Medicine Oncology, Bayer Pharma AG, 13342 Berlin, Germany

Tobias Kiesslich, Department of Internal Medicine I, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria

Tobias Kiesslich, Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria

Author contributions: All authors contributed equally in literature retrieval and evaluation, design and drafting of the manuscript.

Correspondence to: Daniel Neureiter, MD, MA, Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Muellner Hauptstrasse 48, 5020 Salzburg, Austria. d.neureiter@salk.at

Telephone: +43-662-44824737 Fax: +43-662-4482882

Received: November 28, 2013
Revised: February 7, 2014
Accepted: March 12, 2014
Published online: June 28, 2014

Core Tip

Core tip: Pancreatic cancer represents a devastating disease with poor overall survival at advanced stages, and new and effective treatment options are required. Besides genetic mutations, epigenetic dysregulation of oncogenes and tumor suppressor genes is recognized as a novel therapeutic target. Mechanisms underlying DNA methylation, histone acetylation and microRNA regulation and their contribution to pancreatic cancer development and resistance to treatment are highlighted in this review. Potential therapeutic interventions are discussed.